IMID Patients

Immune-mediated inflammatory disease (IMID) is a concept to describe a group of chronic disorders characterized by the activation of multiple immune and inflammatory pathways. Although each IMID targets different tissues and organs, they all share common clinical features and molecular mechanisms. Their etiology is unknown although genetic and environmental factors are crucial determinants of susceptibility. The estimated prevalence of IMIDs is 7–10% in the general population. IMIDs are associated with a high socio-economic impact and are among the main causes of morbidity, disability, and mortality in developed countries

The IMID pathologies investigated by IMIDOMICS are in the field of:

IMIDomics has access to large cross-sectional and longitudinal cohorts of IMID patients:

The therapeutic goals for IMIDs are identical for all of them: to attain rapid control of the local and systemic inflammation and to achieve a long-term disease remission. To prevent tissue damage and reduce the functional disability are the main drivers to improve the quality of life of the patients. All these goals are rarely met in each patient presumably due to failure to address the underlying immunopathology or due to side effects. Frequently, the patients require access to multiple drugs with different mechanism of action and successive treatments throughout life. The future goals for IMIDs management are set towards the identification of better targeted, more effective and less toxic medications